Compare Eli Lilly And Co (LLY) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

VOOG, the Vanguard S&P 500 Growth ETF, trades at $80.98, up 0.28% on the day. The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent news highlights its competitive expense ratio of 0.07% and heavy technology sector concentration, which has driven strong long-term returns but also introduces volatility. A 1:6 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 26, 2026.

The ETF's outlook hinges on the performance of large-cap growth stocks, particularly in technology. Opportunities exist from continued AI-driven growth, but risks include high sector concentration and market sensitivity to tech valuations. Analyst sentiment is generally positive given its low-cost structure and historical performance, though the current bearish technical signal warrants caution.